Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …

Treatment options for chronic myeloid leukemia (CML) have changed dramatically during
the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly improved …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder that affects 5000 new
patients per year in the United States. Prior to 10years ago, durable remission was rare and …

BCR/ABL fusion tyrosine kinase transforms hematopoietic stem cells causing chronic
myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). BCR/ABL regulates …

Degradation of BCR-ABL oncoproteins by heat shock protein 90 (Hsp90) inhibitors in
chronic myelogenous leukemia is expected to overcome resistance to ABL tyrosine kinase …

Effective inactivation of the HER2-HER3 tumor driver has remained elusive because of the
challenging attributes of the pseudokinase HER3. We report a structure-function study of …

Protein kinases (PKs) play crucial roles in cellular proliferation and survival, hence their
deregulation is a common event in the pathogenesis of solid and hematologic malignancies …

Chronic Myeloid Leukemia (CML) is a disease of hematopoietic stem cells which harbor the
chimeric gene Bcr‐Abl. Expression levels of this constitutively active tyrosine kinase are …

BACKGROUND. Leukemias are dependent on Akt/NF‐κB activation and angiogenesis.
METHODS. The antiangiogenic Akt/NF‐κB inhibitor xanthohumol (XN) has in vitro activity …

There are three currently identified secondary resistance mechanisms observed in patients
with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs). These are …